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Abstract Patients (85%) with hepatocellular adenoma
(HCA) are women taking oral contraceptives. They can be
divided into four subgroups according to their genotype/
phenotypefeatures.(1)Hepatocytenuclearfactor1a(HNF1a)
biallelic somatic mutations are observed in 35% of the HCA
cases.Itoccursinalmostallcasesinwomen.HNF1a-mutated
HCA are most of the time, highly steatotic, with a lack of
expression of liver fatty acid binding protein (LFABP) in
immunohistochemistry analyses. Adenomatosis is frequently
detected in this context. An HNF1a germline mutation is
observed in less than 5% ofHCA cases and can be associated
with MODY 3 diabetes. (2) An activating b-catenin mutation
was found in 10% of HCA. These b-catenin activated HCAs
areobservedinmenandwomen,andspeciﬁcriskfactors,such
as male hormone administration or glycogenosis, are associ-
ated with their development. Immunohistochemistry studies
show that these HCAs overexpress b-catenin (nuclear and
cytoplasmic)andglutaminesynthetase.Thisgroupoftumours
has a higher risk of malignant transformation into hepatocel-
lularcarcinoma.(3)InﬂammatoryHCAsareobservedin40%
ofthecases,andtheyaremostfrequentinwomenbutarealso
found in men. Lesions are characterised by inﬂammatory
inﬁltrates, dystrophic arteries, sinusoidal dilatation and duc-
tular reaction. They express serum amyloid A and C-reactive
protein. In this group, GGT is frequently elevated, with a
biological inﬂammatory syndrome present. Also, there are
moreoverweight patientsin thisgroup.Anadditional10% of
inﬂammatory HCAs express b-catenin, and are also at risk of
malignant transformation. (4) Currently, less than 10% of
HCAsareunclassiﬁed.Itishopedthatinthenearfutureitwill
be possible with clinical, biological and imaging data to pre-
dictinwhichofthe2majorgroups(HNF1a-mutatedHCAand
inﬂammatory HCA) the patient belongs and topropose better
guidelines in terms of surveillance and treatment.
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In the West, hepatocellular adenoma (HCA) is a rare
tumour that usually develops in women following oral
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DOI 10.1007/s12072-008-9075-0contraceptive use for a period of more than 2 years. After
the 2005 Bordeaux update on benign hepatocellular nod-
ules [1], we have identiﬁed new molecular features
associated with HCA, which have modiﬁed our under-
standing [2].
HCAs are associated with molecular features
Hepatocellular adenomas are monoclonal tumours [3, 4]i n
which several mutations have been identiﬁed.
The transcription factor 1 (TCF1) gene
The TCF1 gene encodes the hepatocyte nuclear factor 1a
(HNF1a). HNF1a has been identiﬁed as a human tumour
suppressor gene involved in liver tumourigenesis [5].
Indeed biallelic inactivating mutations of this gene were
observed in many HCAs and few hepatocellular carcino-
mas (HCC). The TCF1 gene maps to chromosome 12q24.2,
and encodes the hepatocyte nuclear factor 1a (HNF1a), a
transcription factor involved in hepatocyte differentiation.
HNF1a controls the expression of liver-speciﬁc genes, such
as albumin. In mice, loss of HNF1a activity was associated
with the development of fatty liver, hepatomegaly, hepa-
tocyte dysplasia and proliferation [6]. In HCA tumours
harbouring HNF1a mutations, we observed (a) a repression
of gluconeogenesis coordinated with an activation of gly-
colysis, citrate shuttle and fatty acid synthesis, which may
lead to elevated rates of lipogenesis [7] and (b) a silencing
of L-FABP, which encodes liver fatty acid binding protein
1, suggesting that impaired fatty acid trafﬁcking may also
contribute to the fatty phenotype ([7] and see below).
b-Catenin gene
Chen et al. [8], and later our group, identiﬁed a b-catenin-
activating mutation in a few HCA cases [9, 10]. We have
not observed any HCA cases with both b-catenin mutations
and biallelic inactivation of HNF1a, suggesting that these
two tumourigenic pathways are mutually exclusive. The b-
catenin mutation leads to the activation of the Wnt/b-
catenin pathway that plays a key role in liver physiological
phenomena, such as lineage speciﬁcation, differentiation,
stem cell renewal, epithelial-mesenchymal transition,
zonation, proliferation, cell adhesion and liver regeneration
[2]. Mutations of b-catenin are also found in 20–34% of
hepatocellular carcinomas, suggesting that b-catenin is the
most frequently activated oncogene in HCC [11]. In our
series of HCAs, we showed that b-catenin-activated HCAs
were more at risk of a malignant transformation than other
HCA subtypes [9].
The inﬂammatory HCA
In these tumours, with speciﬁc pathological characteristics
[4, 12], the expression of members of the acute phase
inﬂammatory response, serum amyloid protein (SAA) and
C-reactive protein (CRP), was elevated at both the mRNA
and protein levels [10]. Some inﬂammatory HCA also
demonstrate b-catenin mutation.
Is there a genetic predisposition to HCA development?
HNF1a germline mutations confer a predisposition to both
diabetes (MODY3) [13, 14] and liver adenomatosis. In
1978, Foster described an association between familial
adenomas and diabetes [15]. As most individuals with a
germline HNF1a mutation do not develop liver tumours
[14], the mutations may confer a predisposition to liver
adenomatosis, with incomplete penetrance, and suggest
that modiﬁer genes may be associated with a toxic expo-
sure factor. More than 50% of women with somatic HNF1a
inactivation developed multiple adenomas, suggesting
there is a yet unknown genetic predisposition to developing
HCA. Recently, we identiﬁed CYP1B1 heterozygous
germline inactivating mutations in 15% of women that
have HNF1a-mutated HCA, suggesting that germline
CYP1B1 mutations may also confer predisposition to the
development of sporadic HNF1a-mutated HCA [16].
Patients presenting a familial adenomatous coli polyposis
with a germline APC mutation frequently developed HCA
[17].
We are not any closer to understanding the complexity
of HCA formation; however, the careful analysis of
molecular and clinical data should lead to new discoveries.
The genotype phenotype classiﬁcation
In our institution, approximately 120 HCAs have been
resected (1984–2007). Currently, the number of HCAs
resected range from 5 to 10 cases/year.
Group 1: Hepatocellular adenomas with mutations
of HNF1a
HNF1a mutations are observed in approximately 30–35%
of HCA. Biallelic inactivating HNF1a mutations have been
identiﬁed in tumour tissues: in most cases, both mutations
are of somatic origin, whereas in less than 10% of the
cases, one mutation is germline and the other is somatic.
Correlations with pathological and clinical data have
shown that HNF1a mutations are mostly observed in a
histologically homogeneous group of tumours, character-
ised by marked steatosis, no cytological abnormalities, no
Hepatol Int (2008) 2:316–321 317
123inﬂammatory inﬁltrates and a lack of LFABP expression in
the tumour. Patients with germline HNF1a mutations were
younger than those with somatic mutations, with or without
clinical diabetes, and they frequently had a family history
of liver adenomatosis [9, 10].
Group 2: Hepatocellular adenomas with mutations
of the b-catenin gene
Inourseries,about10%ofHCAsdemonstratedanactivating
b-catenin gene mutation. Correlations with corresponding
pathological and clinical data have shown that tumours in
which b-catenin is mutated are usually characterised by the
occurrence of cytological abnormalities and acinar pattern,
whereas they are less frequently steatotic and without
inﬂammatory features [9]. Nuclear and cytoplasmic b-cate-
nin staining is often heterogeneous, whereas glutamine
synthetase is often more diffusely expressed. HCA with
mutated b-catenin are more frequently interpreted as bor-
derline lesions between HCA and HCC, and are more
frequently associated with the development of unequivocal
HCC than other HCA subtypes [9, 10, 18]. Speciﬁc risk
factors are often found, such as male hormone administra-
tion, glycogenosis and familial polyposis, enhancing the
proportion of male patients. However, death linked to HCC
was a concern for women in this HCA group.
Group 3: Hepatocellular adenomas with inﬂammatory
features
This group (40–50%) of HCA is characterised by the
presence of inﬂammatory inﬁltrates, sinusoidal dilatation,
dystrophic vessels and ductular reaction [4, 12]. They
express inﬂammatory acute phase proteins such as SAA
and CRP [10]. This group, at least partly, corresponds to a
newly characterised entity, previously called telangiectatic
FNH by Wanless et al. [19], which is a variant of HCA;
this variant is often designated as inﬂammatory and/or
telangiectatic HCA depending upon the importance of
inﬂammatory inﬁltrates and/or sinusoidal dilatation.
Approximately 10% of HCA with inﬂammatory features
also have a mutation in the b-catenin gene (which repre-
sents 20% of total of b-catenin-mutated HCA). The risk of
HCC does exist, but it appears to be lower in this group
than in b-catenin-mutated HCA.
Group 4: Hepatocellular adenomas without HNF1a or
b-catenin gene mutations and without the inﬂammatory
protein expression
This group represents less than 5–10% of cases.
Also, some HCA cannot be classiﬁed if all or nearly the
whole tumour is necrotic and/or haemorrhagic.
Clinical and biological implications
Somatic HNF1a-mutated HCA occur almost exclusively in
women, and the discovery of adenomatosis or multiple
adenomas is frequent [10]. Adenomatosis refers to the
presence of multiple adenomas on imaging ([10) [20].
Steatotic adenomas (usually present in HNF1a-mutated
HCA) are easier to identify by imaging techniques, and this
may explain why adenomatosis in our experience appears
to be more frequent in group 1 than in group 3. In fact, it is
often difﬁcult to assess the true number of adenomas, as
small microadenomas are often missed by imaging (if their
size is in the mm range). Microadenomas can be seen on
the surface of the liver (and have so far been described only
in HNF1a group) and on the resected liver. In resected liver
cases, immunostaining is very useful for microadenoma
identiﬁcation (LFABP, SAA or CRP). It is not rare to
identify other types of nodules, particularly focal nodular
hyperplasia (FNH), in patients with multiple adenomas.
The differential diagnosis is usually easier for haemangi-
oma, but may be more difﬁcult for FNH. In this context, we
found that glutamine synthetase (GS) staining was useful in
differentiating FNH from HCA [10].
Identifying b-catenin/GS-positive HCA is of major
interest, due to the correlation between b-catenin activation
and HCC risk of transformation [2, 8, 18, 21].
This study raised the possibility of using liver biopsies
for the identiﬁcation of the various HCA subtypes. Cur-
rently, there is no data relating to the percentage success of
this technique (work in progress). It is well known how
difﬁcult it is to distinguish between dysplastic HCA
exhibiting some cytonuclear abnormalities (corresponding
mainly in our study to b-catenin-activated HCA) and well-
differentiated HCC on a resected specimen. This is espe-
cially signiﬁcant in b-catenin-activated HCA without overt
associated HCC. In our experience, and with the exception
of b-catenin HCA occurring in a speciﬁc context (glyco-
genosis, male hormone administration, etc.) independent of
sex, all cases of HCC have occurred in women (b-catenin-
mutated, either alone or also inﬂammatory), and all b-
catenin-activated HCA without HCC have been found
negative for glypican 3 staining (unpublished data). How-
ever, only 64% of HCC that developed on normal liver
samples were positively stained by glypican 3 [22]; thus,
there is a need to identify new markers of malignant
transformation in b-catenin-activated HCA and therefore
precisely understand the malignant transformation of this
type of HCA.
Inﬂammatory HCA are more often associated with an
increased level of GGT, and occurs more frequently in
overweight patients [10, 23]. In some cases, signs of
chronic anaemia of inﬂammation may be observed. The
link between inﬂammation and/or anaemia is conﬁrmed by
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123their disappearance after surgical removal of the nodule(s)
[24]. It is important to document biological abnormalities
(inﬂammatory and metabolic syndromes) in any suspected
cases of inﬂammatory HCA. The discovery of an inﬂam-
matory HCA in men is troublesome, particularly in those
who are positive for b-catenin. Even though we have never
observed an association with HCC, we cannot ignore that
HCC in non-cirrhotic liver occur in a similar setting (due to
the combination of metabolic syndrome, excess alcohol
consumption, etc.).
Practical attitude
Hepatocellular adenoma is a rare disease occurring in
young women and more rarely in men.
The signiﬁcant correlation between the genotype and
phenotype classiﬁcation has changed our understanding of
the disease.
The ﬁrst interest in this classiﬁcation was to identify
HCA previously classiﬁed as telangiectatic FNH [4, 12]
and to solve difﬁculties in diagnosing between HCA and
FNH [1].
The second interest has been to offer available tools to
classify nodules (and therefore patients), allowing a better
understanding of the natural history of each subgroup,
including their possible regression after menopause. Also,
it sometimes allows us to predict immunopathological
diagnosis on liver biopsies of the tumour, like on resected
specimens, and soon we hope that imaging data will further
enhance our diagnostic criteria (work in progress).
Current data are however too premature to modify, in
depth, the classical rules relating to surveillance and
treatment [25–28]. For now, these rules remain the same.
They can be summarised as follows: stop oral contracep-
tives, and remove any nodule larger than 4–5 cm to avoid
the risk of haemorrhage (frequent) and HCC (rare).
Regarding haemorrhage, HCAs often present radiolog-
ical evidence of minimal intratumoural bleeding. Those
patients may eventually be at a greater risk of major
bleeding than those without.
Women with HCA are said to be at greater risk of
bleeding during pregnancy. Some authors recommend
avoiding pregnancy. However, this risk cannot be esti-
mated at an individual level, and there are cases in which
pregnancies have been uneventful. It seems reasonable to
look for the presence of intratumoural bleeding in any
discovered or known HCA in a pregnant woman, and to
recommend a close follow-up using frequent ultrasound
imaging.
The discovery of a small (\3 cm) b-catenin-mutated
HCA is certainly a strong argument for removing it,
especially in men; however, this may not be the universal
recommendation, as long as we do not understand all the
steps in carcinogenesis, which are probably dependent on
the cause. Some causes of disease, such as glycogenosis,
are at high risk of malignant transformation, and patients
taking male hormones should be monitored extremely
carefully once the drug has been stopped.
Table 1 summarises some general and practical aspects
relating to HCAs and their differential diagnoses.
The future
Better knowledge of the various subgroups may solve
many unanswered questions:
– Is the bleeding risk the same in all groups and does it
occur in nodules smaller than 3–5 cm?
– Is the b-catenin mutation synonymous with a precan-
cerous stage, possibly reversible if the cause is stopped,
or is it a well-differentiated HCC in any case?
– What is the risk of HCC in cases without b-catenin
mutation?
– Are all HCAs of the same subgroup (in multiple HCA/
adenomatosis) exposed to a similar risk of bleeding or
HCC transformation?
As HCA is a rare disease, it is important that each centre
collects data which include recent information (see ﬂow
chart used in our institution). To help clinicians (hepatol-
ogists, radiologists, pathologists and surgeons), we are
presently building a website, part of which will also be
available to patients.
It is likely that new mutations will be discovered,
increasing the speciﬁcity of the classiﬁcation. Also, MRI
and ultrasound (US) contrast agents will allow researchers
to distinguish between the two main subgroups of HCA.
Novel drug treatment should become available, and previ-
ously proposed radiological investigation therapies may be
tested in the future (embolisation, radio frequency) [29, 30].
In the near future, we will be able to propose better
guidelines, particularly in patients with adenomatosis that
are at risk of haemorrhage (particularly troublesome in
pregnant women), and for malignant transformation in two
main areas: surveillance and new modalities of treatment.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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